Does ART prevent HIV transmission among MSM?
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery
Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials
A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV
Boosted protease inhibitor monotherapy as a maintenance strategy
Spatial accessibility and the spread of HIV-1 subtypes and recombinants
Missed opportunities to prevent mother-to-child-transmission
Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care
Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users
Tenofovir use and pregnancy among women initiating HAART
Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting
Putting risk compensation to rest
Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers
Raltegravir central nervous system tolerability in clinical practice
Serotonin syndrome following drug–drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient
Undiagnosed HIV prevalence in France
Undiagnosed HIV prevalence in France
Raltegravir in the prevention of mother-to-child transmission of HIV-1
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
Twelve-month follow-up of Six Week Extended Dose Navirapine randomized controlled trials